Myc-overexpressing triple-negative breast cancer (TNBC) has a greater bioenergetic dependence on FAO, and CPT1A can be pharmaceutically inhibited to reduce energy metabolism in Myc-overexpressing TNBC cells and stop tumor growth in a xenograft model of Myc-overexpressing TNBC (Camarda et al., 2016; Park et al., 2016). The gene discussed is MYC; the disease is triple-negative breast carcinoma.